Company news

Neurocrine Biosciences, Inc. news in 2021

Neurocrine Biosciences, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease

December 6, 2021

Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer

November 29, 2021

Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders

November 21, 2021

Neurocrine Biosciences Reports Third Quarter 2021 Financial Results

October 31, 2021

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021

October 31, 2021

Neurocrine Biosciences to Present ONGENTYS® (opicapone) and INGREZZA® (valbenazine) Data at the American Neurological Association 2021 Virtual Annual Meeting

October 15, 2021

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2021 Financial Results

October 10, 2021

Neurocrine Biosciences Expands Monumental Moments™ Program With World-Renowned Artist Jorge Rodriguez-Gerada to Raise Mental Health Awareness and Honor Those Impacted by the Pandemic

October 7, 2021

Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease

August 4, 2021

Neurocrine Biosciences Reports Second Quarter 2021 Financial Results

August 2, 2021

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results

July 18, 2021

Neurocrine Biosciences Reports First Quarter 2021 Financial Results

May 4, 2021

Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors

April 15, 2021

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results

April 13, 2021

Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)

March 1, 2021

Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results

February 3, 2021

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results

January 19, 2021

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

January 7, 2021

Calls in 2021

Decks in 2021